MATINAS BIOPHARMA HOLDINGS, INC. Contract Liability (Deferred Revenue)
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) had Contract Liability (Deferred Revenue) of $721.00 thousand as of 2022-12-31, per its 10-Q filed 2023-11-08.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Deferred Revenue, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2023-11-08
- 2022-12-31: Contract with Customer, Liability, Current $721.00K.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2022-12-31 | $721.00K 10-Q · filed 2023-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |